Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cemex S.A.B. de C.V. Sponsored ADR (CX) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Cemex S.A.B. de C.V. Sponsored ADRTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

Cemex S.A.B. de C.V. Sponsored ADR vs Ginkgo Bioworks Holdings Inc — how do they compare? Cemex S.A.B. de C.V. Sponsored ADR trades at $9.49 (market cap $13.79B), while Ginkgo Bioworks Holdings Inc trades at $13.09 (market cap $763.64M). The key difference: Cemex S.A.B. de C.V. Sponsored ADR is far larger — about 18.1× Ginkgo Bioworks Holdings Inc's market cap, and Cemex S.A.B. de C.V. Sponsored ADR pays a 1.3% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cemex S.A.B. de C.V. Sponsored ADR for 1 Days and Ginkgo Bioworks Holdings Inc for 7 Days on average.

CXDNA
Market Cap
$13.79B$763.64M
Volume
3,993,9823,204,177
Sector
Basic MaterialsHealth
52-Week High
$13.55$15.83
52-Week Low
$9.12$5.48
Typical Hold Time
1 Days7 Days
Enterprise Value
$19.79B$865.59M
Dividend Yield
1.3%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cemex S.A.B. de C.V. Sponsored ADR

No Aura AI signal available yet.

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CX

No sentiment data available yet.

DNA
47% Buy53% Sell
Avg holding period · 7 Days

Top news

Latest headlines on both assets

About Cemex S.A.B. de C.V. Sponsored ADR

Cemex produces, distributes, markets, and sells cement, ready-mix concrete, aggregates, and other construction materials. Its operations serve markets around the world.

Read more on CX →

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA →